Coronavirus / COVID

Two cases in the United States showed reinfection after administration of the m-RNA vaccines may complicate protection against new variants, but lend support to a potential need for a booster.

The Johnson & Johnson shot showed an efficacy of 66.9% and 66.1% on the 2 primary endpoints, with a higher efficacy against severe-critical disease.

While no evidence of any viral RNA was detected in patients brain cells, investigators found a significant amount of neurological damage.

High levels of anxiety among immunocompromised children and their guardians highlights the need to clearly define COVID-19 risk.

Federal regulators authored a 12 page report citing several examples of misconduct within the plant, including improperly trained employees.

Simple daily measures could help to lower the risk of severe disease and transmission, including using mouthwash.

Severe blood clots reported with 2 COVID-19 vaccines are rare, but possible heightening of vaccine hesitancy would lower floodgates to pandemic waves

A marker that triggers T cells to fight an infection in the gut was found in small numbers in those with a SARS-CoV-2 infection.

The SAA biomarker could allow physicians the opportunity to better care for and manage a patient’s course of disease.

The committee stressed that the events are exceedingly rare, and that the vaccine's benefits outweigh the potential risks.

The Centers for Disease Control and Prevention (CDC) announced that doing so offers very little in terms of protecting against transmission of the airborne virus.

Investigators incorporated universal HIV screening into COVID-19 testing at a Chicago hospital emergency department (ED).

Vaccine rollout in Germany intensifies as more doses are delivered to the country.

A cardiology expert discusses the unique and currently investigated relationship between COVID-19, adenovirus vaccines, and thrombotic events.

Pathologic antibodies to platelet factor 4 in patients who developed clots after the AstraZeneca vaccine indicates treatment include non-heparin anticoagulant.

Results from the study data reinforce the need to adhere to public health measures by people who have been vaccinated.

The decision follows emerging data showing prevalent virus variants are unaffected by the monoclonal antibody.

The company wants to transition to combination therapy of bamlanivimab and etesevimab together for COVID-19 treatment.

While RT-PCR testing is difficult for confirming a reinfection with the virus, whole genome sequencing may be a more reliable measure.

The ongoing pandemic has caused a severe decrease in childhood vaccinations, while some rates have recovered, others have not and clinicians are urging caregivers to have their children receive their shots.

Study hoping to show reduced need for respiratory support with the approach failed to do so, though it does appear to limit the need for intubation.

Study finds a 10% reinfection rate amongst a mostly 18-20 year old United States Marine population in a closed setting.

The 2 shot mRNA vaccine has a high efficacy against COVID-19, but long term data for its protection is not there yet, and emerging variants may present a challenge.

Antimicrobials were commonly prescribed during the first wave of the pandemic, and clinicians were successfully guided by antimicrobial stewardship programs.